← Leaderboards
Jane E Reusch
University Of Colorado Denver
$6,071,855
Attributed
$8,511,417
Total exposure
18
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,511,417 · 16
VA$0 · 2
By mechanism
R01$5,926,694 · 3
P30$2,063,132 · 3
M01$521,591 · 10
I01$0 · 2
Top collaborators
- Zhenqi Liu4 shared
- Judith G Regensteiner4 shared
- Ivor S Douglas2 shared
- Rachel Wong1 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Joann Lindenfeld$2,694,462
- Stanley Michinobu Kanai$494,014
- Benjamin S Frank$560,550
- Douglas K Novins$3,835,300
- Thomas E Forman$93,029
Others in their field
Top investigators on “Diabetes Mellitus”
- Jeffrey P Krischer · University Of South Florida$608,226,434
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$177,347,135
- John M Lachin · George Washington University$155,262,668
- David M Nathan · Massachusetts Institute Of Technology$142,806,023
- Judith S Hochman · New York University School Of Medicine$100,149,457
- Jose A Luchsinger · Columbia University Health Sciences$75,551,718
Research focus
Diabetes MellitusReportingIn VivoMediatingResponseImpairmentExerciseBlood VesselsMortalityCardiovascular SystemInsulinExperimental StudyMusclePerfusionSkeletal MuscleCardiovascular Risk FactorClinical ResearchHuman SubjectInsulin ResistanceNon-Insulin-Dependent Diabetes MellitusImpaired CapacityExercise CapacityOxygenFunctional Disorder
Grant awards (53)
Role of Microvascular insulin resistance and cardiorespiratory fitness in diabetes$711,928
R01 · FY2025 · DK · contact PI
P&F Program$343,014
P30 · FY2025 · DK · contact PI
Role of Microvascular insulin resistance and cardiorespiratory fitness in diabetes$683,451
R01 · FY2024 · DK · contact PI
P and F Program$344,023
P30 · FY2024 · DK · contact PI
Targeting Microvascular Contributors to Impaired Functional Exercise Capacity in Diabetes$0
I01 · FY2024 · VA · contact PI
Role of Microvascular insulin resistance and cardiorespiratory fitness in diabetes$711,928
R01 · FY2023 · DK · contact PI
Impact of SARS CoV2 on post-hospital recovery of carbohydrate and muscle metabolism: role of endothelial injury$351,222
R01 · FY2023 · DK · contact PI
P and F Program$344,024
P30 · FY2023 · DK · contact PI
Incidence and severity of new onset diabetes associated with SARS-CoV-2 infection$405,975
R01 · FY2022 · DK · contact PI
Impact of SARS CoV2 on post-hospital recovery of carbohydrate and muscle metabolism: role of endothelial injury$385,364
R01 · FY2022 · DK · contact PI
P and F Program$344,024
P30 · FY2022 · DK · contact PI
Cardiovascular Mechanisms of Exercise Intolerance in Diabetes and the Role of Sex$0
I01 · FY2022 · VA · contact PI
Targeting Microvascular Contributors to Impaired Functional Exercise Capacity in Diabetes$0
I01 · FY2022 · VA · contact PI
Role of Microvascular insulin resistance and cardiorespiratory fitness in diabetes$695,115
R01 · FY2021 · DK · contact PI
Impact of SARS CoV2 on post-hospital recovery of carbohydrate and muscle metabolism: role of endothelial injury$398,573
R01 · FY2021 · DK · contact PI
P and F Program$344,023
P30 · FY2021 · DK · contact PI
Targeting Microvascular Contributors to Impaired Functional Exercise Capacity in Diabetes$0
I01 · FY2021 · VA · contact PI
Cardiovascular Mechanisms of Exercise Intolerance in Diabetes and the Role of Sex$0
I01 · FY2021 · VA · contact PI
P and F Program$344,024
P30 · FY2020 · DK · contact PI
Cardiovascular Mechanisms of Exercise Intolerance in Diabetes and the Role of Sex$0
I01 · FY2020 · VA · contact PI
Targeting Microvascular Contributors to Impaired Functional Exercise Capacity in Diabetes$0
I01 · FY2020 · VA · contact PI
Cardiovascular Mechanisms of Exercise Intolerance in Diabetes and the Role of Sex$0
I01 · FY2019 · VA · contact PI
Targeting Microvascular Contributors to Impaired Functional Exercise Capacity in Diabetes$0
I01 · FY2019 · VA · contact PI
Targeting Microvascular Contributors to Impaired Functional Exercise Capacity in Diabetes$0
I01 · FY2018 · VA · contact PI
Cardiovascular Mechanisms of Exercise Intolerance in Diabetes and the Role of Sex$0
I01 · FY2018 · VA · contact PI
Pharmacological Restoration of Diabetic Vascular Dysfunction$0
I01 · FY2017 · VA · contact PI
Cardiovascular Mechanisms of Exercise Intolerance in Diabetes and the Role of Sex$0
I01 · FY2017 · VA · contact PI
Pharmacological Restoration of Diabetic Vascular Dysfunction$0
I01 · FY2016 · VA · contact PI
Pharmacological Restoration of Diabetic Vascular Dysfunction$0
I01 · FY2015 · VA · contact PI
Pharmacological Restoration of Diabetic Vascular Dysfunction$0
I01 · FY2014 · VA · contact PI
Transcriptional Regulation of PDGF Receptor Alpha$64,158
R01 · FY2009 · DK · contact PI
Transcriptional Regulation of PDGF Receptor Alpha$308,965
R01 · FY2008 · DK · contact PI
EFCTS FREE FATTY ACID-INDCD ENDTHLIAL DYSFNCTN&INSULIN RSISTNC ON EXRCZ CPCTY$1,898
M01 · FY2008 · RR · contact PI
ROSIGLITAZONE THRPY FOR PREV OF COR ARTERY DISEASE IN PTS W/IMPAIRD GLUCOSE TOL$989
M01 · FY2008 · RR · contact PI
Transcriptional Regulation of PDGF Receptor Alpha$306,778
R01 · FY2007 · DK · contact PI
EFCTS FREE FATTY ACID-INDCD ENDTHLIAL DYSFNCTN&INSULIN RSISTNC ON EXRCZ CPCTY$16,158
M01 · FY2007 · RR · contact PI
ROSIGLITAZONE THRPY FOR PREV OF COR ARTERY DISEASE IN PTS W/IMPAIRD GLUCOSE TOL$8,415
M01 · FY2007 · RR · contact PI
Transcriptional Regulation of PDGF Receptor Alpha$306,737
R01 · FY2006 · DK · contact PI
ROSIGLITAZONE THRPY FOR PREV OF COR ARTERY DISEASE IN PTS W/IMPAIRD GLUCOSE TOL$11,140
M01 · FY2006 · RR · contact PI
Transcriptional Regulation of PDGF Receptor Alpha$301,683
R01 · FY2005 · DK
ROSIGLITAZONE THRPY FOR PREV OF COR ARTERY DISEASE IN PTS W/IMPAIRD GLUCOSE TOL$4,861
M01 · FY2005 · RR
Transcriptional Regulation of PDGF Receptor Alpha$294,817
R01 · FY2004 · DK
GLUCAGON RECEPTOR ANTAGONIST (BAY 27-9955) IN NIDDM$190,747
M01 · FY2002 · RR
GLUCAGON RECEPTOR ANTAGONIST (BAY 27-9955) IN NIDDM$190,747
M01 · FY2001 · RR
GLUCAGON RECEPTOR ANTAGONIST (BAY 27-9955) IN NIDDM$0
M01 · FY2001 · RR
AMINOGUANIDINE IN DIABETIC PATIENTS WITH OVERT DIABETIC NEPHROPATHY$32,212
M01 · FY2000 · RR
BRL49653C IN PTS WITH NIDDM WHO ARE INADEQ CONTROLLED ON INSULIN MONOTHERAPY$32,212
M01 · FY2000 · RR
HOE 901 INSULIN WITH NPH HUMAN INSULIN IN TYPE II DIABETES$32,212
M01 · FY2000 · RR
AMINOGUANIDINE IN DIABETIC PATIENTS WITH OVERT DIABETIC NEPHROPATHY$0
M01 · FY2000 · RR
BRL49653C IN PTS WITH NIDDM WHO ARE INADEQ CONTROLLED ON INSULIN MONOTHERAPY$0
M01 · FY2000 · RR
HOE 901 INSULIN WITH NPH HUMAN INSULIN IN TYPE II DIABETES$0
M01 · FY2000 · RR
GLUCAGON RECEPTOR ANTAGONIST (BAY 27-9955) IN NIDDM$0
M01 · FY2000 · RR
GLUCAGON RECEPTOR ANTAGONIST (BAY 27-9955) IN NIDDM$0
M01 · FY2000 · RR